Iol 2006, 574:14966. 10. Gudasheva TA, Voronina TA, Ostrovskaya RU, Rozantsev GG, Vasilevich NI, FP Agonist web Trofimov SS, Kravchenko EV, Skoldinov AP, Seredenin SB: Synthesis and antimnestetic activity of a series of N-acylprolyl-containing dipeptides. Eur J Med Chem 1996, 31:15157. 11. Seredenin SB, Voronina TA, Gudasheva TA, Ostrovskaya RU, Rozantsev GG, Skoldinov AP, Trofimov SS, Halikas J, Garibova TL: Biologically active N-acylprolyldipeptides having antiamnestic, antihypoxic effects. US patent 1995. No. 5.439.930. 12. Ostrovskaya RU, Gudasheva TA, Trofimov SS, Kravchenko EV, Firova FV, Molodavkin GM, Voronina TA, Seredenin SB: GVS-111, an AcylprolylContaining Dipeptide With Nootropic Properties. In Biological Basis of Person Sensitivity to Psychotropic Drugs. Edited by Seredenin SB, Longo V, Gaviraghi G. UK: Graffhan Press Ltd; 1994:791. 13. Boiko SS, Ostrovskaya RU, Zherdev VP, Korotkov SA, Gudasheva TA, Voronina TA, Seredenin SB: Pharmacokinetics of new nootropic acylprolyldipeptide and itsConclusions Cognitive enhancer noopept exerts a protective effect against A255-induced toxicity in PC12 cells. The protective ability of noopept probably outcomes from moderate suppression of oxidative anxiety and intracellular calcium influx, stabilization of mitochondrial function and lowering of apoptosis. One more doable mechanism by which this compound protects cells from amyloid toxicity may be related towards the reduce of tau phosphorylation and, sooner or later, neurite stabilization and outgrowth.Abbreviations A: -Amyloid; AchE: Acetylcholinesterase E; AD: Alzheimer disease; APOE: Apolipoprotein E; APP: Amyloid precursor protein; BDNF: Brain-derived neurotrophic issue; DMEM: Dulbecco’s modified Eagle’s medium; FBS: Fetal bovine serum; FITC: Fluorescein isothiocyanate; HBSS: Hank’s BalancedOstrovskaya et al. Journal of Biomedical Science 2014, 21:74 http://jbiomedsci/content/21/1/Page 9 of14.15.16.17.18.19.20.21.22.23. 24.25.26.27. 28.29.30.31.32. 33.penetration across the blood rain barrier right after oral administration. Bull Exp Biol Med 2000, 129:35961. Gudasheva TA, Bojko SS, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB: The big metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet 1997, 22:24552. Ostrovskaya RU, Romanova GA, Barskov IV, Shanina EV, Gudasheva TA, Victorov IV, Voronina TA, Seredenin SB: Memory restoring and neuroprotective effects in the proline containing dipeptide, GVS-111, inside a photochemical stroke model. Behav Pharmacol 1999, ten:54953. Pealsman A, Hoyo-Vadillo C, Seredenin SB, Gudasheva TA, Ostrovskaya RU, Busciglio J: GVS-111 prevents oxidative harm and IL-4 Inhibitor custom synthesis apoptosis in standard and Down’s syndrome human cortical neurons. Int J Dev Neurosci 2003, 21:11724. Ostrovskaia RU, Gudasheva TA, Voronina TA, Seredenin SB: The original novel nootropic and neuroprotective agent Noopept. Eksp Klin Farmakol 2002, 65(5):662. Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RDE, Gudasheva TA, Samokhin AN, Seredenin SB, Noppe W, Sherstnev VV, Morozova-Roche LA: The nootropic and neuroprotective proline-containing dipeptide Noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s Disease model. J Psychopharmacol 2007, 21:61119. Ostrovskaya RU, Belnik AP, Storozheva ZI: Noopept efficiency in experimental Alzheimer Disease (cognitive deficiency caused by beta-amyl.
